Consultation record
Submissions noted, no amendment
The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Submissions
109 documents · page 1 of 4
Table 1. Submissions with this disposition, on this page.
| Reference | Consultation | Respondent | Point raised |
|---|---|---|---|
| DRAFT-CERTAINTY-FR/006 | Draft revision of the Institute’s certainty assessment framework… | Dr Lorcan Whitmarsh-Obi | The document should describe how an assessment becomes a decision |
| DRAFT-SUPPLIER-RUB/002 | Draft supplier evaluation rubric | Georgiana Zimmerthal | Declared interests should appear on the document rather than on a separate page |
| DRAFT-SEMAGLUTIDE-/009 | Draft monograph: semaglutide, version 3 | Vittoria Ylönen | The monograph should not describe how the compound is supplied outside a regulated route |
| DRAFT-TIRZEPATIDE-/004 | Draft monograph: tirzepatide, version 2 | Dr Xenia Nyquist-Obiora | Guidance on lyophilised storage is missing |
| DRAFT-WEIGHT-REGAI/008 | Draft synthesis: weight change after discontinuation of an incretin… | Dr Yaa Kettlewell | Baseline imbalance in a small contributing trial is not remarked on |
| DRAFT-FUNDING-POLI/004 | Draft funding and sponsorship policy | Kamila Ubertini | The Institute publishes no telephone number and no messaging channel |
| DRAFT-CITATION-POL/007 | Draft citation policy | Dr Perpetua Haverkamp-Diallo industry | The disclosure requirements exceed those of comparable bodies |
| DRAFT-PROGRAMME-RE/004 | Draft policy: labelling of Institute-constructed programme records | Kolawole Oppenheimer-Ade | The Institute publishes no telephone number and no messaging channel |
| DRAFT-ENDOTOXIN-ST/004 | Draft standard: bacterial endotoxin testing of peptide presentations | Stellan Cholmondeley-Ade | A superseded version should remain reachable from the version that replaced it |
| DRAFT-GLP1-OBESITY/015 | Draft synthesis: glucagon-like peptide-1 receptor agonists for weight… | Georgiana Zimmerthal | Declared interests should appear on the document rather than on a separate page |
| DRAFT-THYROID-C-CE/008 | Draft safety review: the rodent thyroid C-cell signal and its human… | Dr Yaa Kettlewell | Baseline imbalance in a small contributing trial is not remarked on |
| DRAFT-THYROID-C-CE/010 | Draft safety review: the rodent thyroid C-cell signal and its human… | Dr Emiliana Ollerenshaw | Declared interests should appear on the document rather than on a separate page |
| DRAFT-SUPPLIER-DOS/005 | Draft format of the supplier dossier series | Ulysses Bellingham-Ojo | A multi-part document does not indicate how many parts it has |
| DRAFT-PEOPLE-REGIS/002 | Draft policy on the register of members and reviewers | Dr Beatrijs Hazelrigg | Assessment committee meetings are held in private |
| DRAFT-PEOPLE-REGIS/006 | Draft policy on the register of members and reviewers | Kolawole Oppenheimer-Ade | The Institute publishes no telephone number and no messaging channel |
| DRAFT-PEOPLE-REGIS/008 | Draft policy on the register of members and reviewers | Vittoria Ylönen | Declared interests should appear on the document rather than on a separate page |
| DRAFT-PEOPLE-REGIS/013 | Draft policy on the register of members and reviewers | Wilhelmina Erlingsson | A submission the Institute declines to publish leaves no trace |
| DRAFT-CORRECTIONS-/007 | Draft corrections and versioning policy | Georgiana Zimmerthal | Declared interests should appear on the document rather than on a separate page |
| DRAFT-CORRECTIONS-/017 | Draft corrections and versioning policy | Dr Perpetua Haverkamp-Diallo industry | The disclosure requirements exceed those of comparable bodies |
| DRAFT-STABILITY-ST/011 | Draft standard: freeze–thaw and in-use stability assessment of… | Vittoria Ylönen | Declared interests should appear on the document rather than on a separate page |
| DRAFT-INDICATION-S/008 | Draft indication set and anchor outcomes | Anselm Mountstephen | A superseded version should remain reachable from the version that replaced it |
| DRAFT-ADOLESCENT-S/011 | Draft synthesis: incretin receptor agonists in adolescents | Dr Oisín Rautavaara | Baseline imbalance in a small contributing trial is not remarked on |
| DRAFT-ADOLESCENT-S/016 | Draft synthesis: incretin receptor agonists in adolescents | Quentin Whitmarsh-Obi | A superseded version should remain reachable from the version that replaced it |
| DRAFT-ANALYTICAL-S/005 | Draft analytical review: surveys of unregulated peptide supply | Dr Anselm Thorsby-Nakamura | The chain of custody between purchase and analysis is not described |
| DRAFT-ANALYTICAL-S/007 | Draft analytical review: surveys of unregulated peptide supply | Gervase Crickhowell | Whether the analyst knew the source of each sample is not reported |
| DRAFT-ANALYTICAL-S/008 | Draft analytical review: surveys of unregulated peptide supply | Professor Bartolomeu Nkosi-Lindegaard | Contributing surveys anonymise their sources to different degrees |
| DRAFT-ANALYTICAL-S/013 | Draft analytical review: surveys of unregulated peptide supply | Stellan Cholmondeley-Ade | A superseded version should remain reachable from the version that replaced it |
| DRAFT-REGISTRY-STR/003 | Draft structure of the document registry | Dr Emiliana Ollerenshaw | Declared interests should appear on the document rather than on a separate page |
| DRAFT-TOOLS-DISCLA/006 | Draft terms for the Institute’s calculators | Kolawole Oppenheimer-Ade | The Institute publishes no telephone number and no messaging channel |
| DRAFT-TOOLS-DISCLA/011 | Draft terms for the Institute’s calculators | Amara Vandergraaf | A submission the Institute declines to publish leaves no trace |
page 1 of 4